Dr. Paul Huang's research focuses on the roles of nitric oxide (NO) in cardiovascular disease and metabolism, using techniques ranging from molecular biology, physiology, and genetically altered mouse models, to human translational studies and induced pluripotent stem (iPS) cell approaches. His research laboratory is studying how the metabolic abnormalities seen in diabetes and obesity affect vascular function and predispose to cardiovascular disease, including stroke and heart attack. His most recent work shows the importance of eNOS phosphorylation to atherosclerosis, stroke, and insulin resistance. Clinically, Dr. Huang leads the Cardiac Metabolic Syndrome Program in the MGH Cardiovascular Disease Prevention Center. He is PI of the translational research CAMP MGH Study (MGH Cardiology and Metabolic Patient Cohort), the first and largest cohort derived from MGH Heart Center patients with detailed phenotyping, genotyping, and physiologic characterization of glucose tolerance and vascular dysfunction. As a member of the Harvard Stem Cell Institute, Dr. Huang is deriving iPS cells from subjects carrying genetic variants that increase risk for type 2 diabetes to test beta cell function, and from subjects with chemotherapy induced cardiomyopathy to test cardiac myocytes contractility.